Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Vor Biopharma
< Previous
1
2
3
Next >
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
Today 16:05 EDT
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
September 08, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio To Participate in Upcoming September Conferences
September 01, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Appoints David Zaccardelli to Board of Directors
July 07, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
June 08, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
June 08, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
May 14, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 30, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
March 30, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Announces $75 Million Private Placement with TCGX
March 27, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 23, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
February 23, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
December 23, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Announces $150 Million Private Placement
December 15, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
November 10, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
November 10, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
November 08, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio to Participate in Upcoming Investor Conferences
November 07, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
